Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy

Sponsor
Pusan National University Hospital
Study ID
NCT01950741
Phase
PHASE4
Status
Completed

Conditions

  • Exudative Age-related Macular Degeneration
  • Polypoidal Choroidal Vasculopathy

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • aflibercept — DRUG
    Aflibercept is injected intravitreally though the pars plana using 30G needle-attached syringe.

Study Details

Effects of VEGF Trap-Eye (aflibercept) in treatment-naive polypoidal choroidal vasculopathy (PCV) will be evaluated.

Key Dates

Start date
Sep 30, 2013
Status verified
Mar 2016
Primary completion
May 31, 2015
Completion
Aug 31, 2015

Study Design

Enrollment
48 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: aflibercept
    Aflibercept 2 mg is injected into the vitreous cavity. Injections are given monthly three times, then are given bi-monthly to 12 months (month 0, 1, 2, 4, 6, 8, and 10; total 7 injections for 1 year).

Primary Outcome Measure

Percentage of Patients Lose Visual Acuity Less Than 15 Letters [ Time Frame: 12 months ]

Related Studies